Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2015

View Archived Issues

Immune Pharmaceuticals enters exclusive license for novel bispecific antibody technology

University of Wisconsin generates vocal cord mucosae in vitro

HDAC inhibitor AR-42 prevents cancer cachexia in animal models

Initiation of phase III trial of CAM-2038 in opioid-dependent patients

Discovery Labs starts phase IIb trial of Aerosurf in premature infants with RDS

Minerva Neurosciences completes recruitment in phase IIb trial of MIN-101 in schizophrenia

FDA grants rare pediatric disease designation to RGX-111 for MPS I

TeaRx's oral anticoagulant Tearexaban completes phase II studies

Prexton Therapeutics plans first-in-human study of PXT-002331

Lixte licenses LB-100 rights in Asia to Taipei Medical University

Oryzon Genomics receives Spanish government funding for two projects

Six-panel biosignature shows promise as a point-of-care screening test for TB

Hutchison Medi Pharma plans phase I trial of HMPL-689

Epizyme starts trials of EZH2 inhibitor tazemetostat in INI1-negative tumors

CDK7 expression shows promise as a prognosis biomarker in TNBC

SNPs near CTNNA2 may be associated with impulsivity

NeuroDerm starts phase II trial comparing two dosing regimens of ND-0612H

Bristol-Myers Squibb patents MGAT2 inhibitors

GlaxoSmithKline describes STING modulators

Bristol-Myers Squibb reports development of NS5B inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...